Biotech News
Related news
OTLKOutlook2026-06-01 12:46 EST
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-05-26 11:00 EST
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
RHHBYRoche Holdings AG2026-07-24 10:15 EST
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
LENZLenz Therapeutics Inc2026-06-07 23:30 EST
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
RHHBYRoche Holdings AG2026-09-30 05:00 EST
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
OCGNOcugen2026-09-25 11:02 EST
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
OCULOcular Therapeutix2026-09-15 11:00 EST
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
OCSOculis2026-08-03 08:00 EST
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
SGHTSight Sciences2026-08-04 21:38 EST
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
TARSTarsus Pharmaceuticals2026-08-06 11:01 EST
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-10-06 13:20 EST
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
OTLKOutlook2026-10-01 13:01 EST
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Stock data
- Close
- 0.57 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States